Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other financing activities (2019 - 2023)

10x Genomics' Other financing activities history spans 5 years, with the latest figure at $5.8 million for Q1 2023.

  • For Q1 2023, Other financing activities rose 7.49% year-over-year to $5.8 million; the TTM value through Dec 2023 reached $5.8 million, up 7.49%, while the annual FY2023 figure was $5.8 million, 7.49% up from the prior year.
  • Other financing activities for Q1 2023 was $5.8 million at 10x Genomics, up from $5.4 million in the prior quarter.
  • Across five years, Other financing activities topped out at $5.8 million in Q1 2020 and bottomed at -$1.9 million in Q3 2019.
  • The 5-year median for Other financing activities is $5.0 million (2021), against an average of $3.2 million.
  • The largest annual shift saw Other financing activities dropped 13.99% in 2021 before it rose 7.58% in 2022.
  • A 5-year view of Other financing activities shows it stood at -$1.9 million in 2019, then soared by 100.1% to $2000.0 in 2020, then soared by 251300.0% to $5.0 million in 2021, then rose by 7.58% to $5.4 million in 2022, then rose by 7.49% to $5.8 million in 2023.
  • Per Business Quant, the three most recent readings for TXG's Other financing activities are $5.8 million (Q1 2023), $5.4 million (Q1 2022), and $5.0 million (Q1 2021).